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We report longitudinal diffusion-weighted magnetic resonance imaging (DW-MRI) and dynamic contrast enhanced
(DCE)-MRI (7 T) studies designed to identify functional changes, prior to volume changes, in trastuzumab-sensitive
and resistant HER2+ breast cancer xenografts. Athymic mice (N = 33) were subcutaneously implanted with
trastuzumab-sensitive (BT474) or trastuzumab-resistant (HR6) breast cancer cells. Tumor-bearing animals were
distributed into four groups: BT474 treated and control, HR6 treated and control. DW- and DCE-MRI were
conducted at baseline, day 1, and day 4; trastuzumab (10 mg/kg) or saline was administered at baseline and day 3.
Animals were sacrificed on day 4 and tumors resected for histology. Voxel-based DW- and DCE-MRI analyses
were performed to generate parametric maps of ADC, Ktrans, and ve. On day 1, no differences in tumor size were
observed between any of the groups. On day 4, significant differences in tumor size were observed between
treated vs. control BT474, treated BT474 vs. treated HR6, and treated vs. control HR6 (P b .0001). On day 1, ve was
significantly higher in the BT474 treated group compared to BT474 control (P = .002) and HR6 treated (P = .004).
On day 4, ve and K
trans were significantly higher in the treated BT474 tumors compared to BT474 controls
(P = .0007, P = .02, respectively). A significant decrease in Ki67 staining reinforced response in the BT474 treated
group compared to BT474 controls (P = .02). This work demonstrated that quantitative MRI biomarkers have the
sensitivity to differentiate treatment response in HER2+ tumors prior to changes in tumor size.
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The human epidermal growth factor receptor 2 (HER2) is over-
expressed in approximately 25%of all breast cancers [1,2], and is usually
indicative of a more aggressive disease and poorer prognosis [2].
Consequently, specific anti-HER2 therapeutics, such as trastuzumab
(Herceptin®, Genentech, San Francisco, CA), have been developed that
specifically target HER2 and disrupt downstream signaling pathways
[3–5].When administered with traditional chemotherapy, trastuzumab
extends overall survival and slows disease progression in patients with
HER2-overexpressing breast cancer [6,7]. Despite the observed survival
benefits, trastuzumab is effective in only 25% to 50% of this patient
population [8,9], and a majority of patients with metastatic breast
cancer that initially respond to treatment will eventually progress.
Furthermore, approximately 15% of patients that receive trastuzumab
in the adjuvant setting will eventually develop metastatic disease [4].
These variable and unpredictable patient outcomes emphasize the need
to develop reliable assessments of disease response early during the
course of therapy. If a reliable method to assess early response were
available, unsuccessful drugs could be replaced with potentially more
effective therapy.
The main tumor cell-autonomous mechanism of action of
trastuzumab is inhibition of HER2 homodimerization and down-
stream signaling of the phosphatidylinositol-3 kinase (PI3K) pathway
leading to an inhibition of cell-cycle progression and survival [2]; this
implies that PI3K regulated processes, e.g., cellular proliferation and
apoptosis [10], are potential biomarkers of clinical response to
trastuzumab. As a secondary mechanism of action, trastuzumab has
been observed to alter tumor microvasculature causing normalization
and regression of tumor associated blood vessels and a reduction in
vessel diameter, volume, and permeability [11,12]. Additionally, gene
expression assays reveal that pro-angiogenic factors, such as vascular
endothelial growth factor (VEGF), are downregulated [11,12]. In
contrast, the anti-angiogenic factor thrombospondin 1 is upregulated
after trastuzumab treatment [11]. Thus, biomarkers reflecting tumor
vessel architecture and function may also be useful in assessing early
clinical response to trastuzumab.
There are a number of imaging techniques that report on specific
characteristics of the tumor microenvironment and response to
therapy. Diffusion-weighted magnetic resonance imaging (DW-
MRI) is a technique that provides a noninvasive, quantitative
characterization of tumor cytoarchitecture [13]. DW-MRI depends
on the microscopic, thermally-induced behavior of water molecules
moving in a random pattern, referred to as Brownian motion. In a
system defined by small compartments (e.g., cellular tissues) that are
separated by semi-permeable membranes, the rate of Brownian
motion or self-diffusion will be less than that of free diffusion. In
cellular tissues, this rate of self-diffusion is described by an apparent
diffusion coefficient (ADC), which is influenced by the number,
permeability, and separation of barriers that act to restrict the free
diffusion of water molecules [14]. DW-MRI data can be used to
construct parametric maps of the ADC, and in well-controlled
situations, ADC has been shown to correlate inversely with tissue cell
density [15]. DW-MRI has been used to assess response to a variety of
therapies in both preclinical models [16–18] and clinical studies of
breast cancer [19–21].
Dynamic contrast enhanced MRI (DCE-MRI) is an imaging
technique that is sensitive to changes in physiological characteristics of
tumor microvasculature [22]. DCE-MRI characterizes the pharma-
cokinetics of an injected contrast agent (CA) as it enters and exits aregion of interest (ROI) or tissue. By acquiring serial T1-weighted
images of the MRI signal over time, the kinetics of the CA can be
quantified using (for example) a two-compartment model to estimate
biologically relevant parameters relating to tumor microvasculature,
such as, blood flow, vessel permeability, and tissue volume fractions.
These quantitative measurements have been used to assess treatment
response in a variety of cancer models and treatment regimens
[14,23,24]. More recently, the clinical utility of DCE-MRI to predict
responders earlier in the course of therapy (either chemotherapy,
radiotherapy or a combination) has been reported in breast
cancer [25].
Although DW-MRI and DCE-MRI have been investigated in
both preclinical and clinical settings, translation into routine clinical
care has been limited. This can be attributed to the inadequate
understanding of whether these imaging protocols can predict
therapeutic efficacy, as well as the lack of validation (via e.g.,
histological analysis) to assist in the interpretation of the imaging data
[13,26]. Thus, the primary objectives of this study were to determine
if DW-MRI and DCE-MRI can assess early treatment response (i.e.,
before changes in tumor size) in trastuzumab-sensitive xenografts.
We also explored the sensitivity of DW-MRI and DCE-MRI to
differentiate between trastuzumab responsive and resistant HER2-
overexpressing xenografts after exposure to treatment. Lastly, we
performed immunohistochemistry (IHC) analyses that reflect on
cellular proliferation and microvasculature in order to investigate the
relationship between the imaging data and the underlying biology.
This study provides insight into translational quantitative imaging
metrics that have the potential to be applied towards the
personalization of HER2+ breast cancer treatment regimens.
Materials and Methods
Cell Lines
Trastuzumab sensitive (BT474) and resistant (HR6) cell lines were
generously supplied from the Laboratory of Dr. Carlos Arteaga
(Vanderbilt University, Nashville, TN) and cultured in improved
minimal essential medium (IMEM, Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum and 1% insulin at
37°C in a humidified, 5% CO2 incubator. The HR6 cell line was
developed in vivo from the BT474 cell line as described previously
[27]. To maintain trastuzumab resistance, HR6 cells were cultured
with 10 μg/ml trastuzumab [27]. Trastuzumab was purchased from
the Vanderbilt University Medical Center Outpatient Pharmacy
(Nashville, TN). Both cell lines were harvested with trypsin at
approximately 85% confluence for inoculation.
Xenograft Models
Female athymic mice (N = 33, 4–6 weeks old, Harlan Laboratories,
Indianapolis, IN) were implanted with 0.72 mg, 60-day release, 17β-
estradiol pellets (Innovative Research of America, Sarasota, FL.
Twenty-four hours later, BT474 or HR6 cells (~1 × 107) grown to
~85% confluence were suspended in a 100 μL volume with a 1:10
ratio of growth factor-reduced Matrigel and IMEM and were injected
subcutaneously into the right flank. Tumor volumes were measured
once per week using calipers. A 26-gauge jugular catheter was
surgically implanted two days prior to the start of imaging. Mice were
anesthetized with 2% isoflurane in pure oxygen mixture for all
surgical procedures and imaging. Our institution's Animal Care and
Use Committee approved all animal procedures.
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which was typically four to eight weeks post cell inoculation. Mice
were grouped into four cohorts: trastuzumab and vehicle treated
BT474 cohorts, and trastuzumab and vehicle treated HR6 cohorts.
Animals were imaged at three time points: a baseline scan acquired
prior to therapy, and then two subsequent imaging sessions at days
1 and 4, which were 24 hours post first and second treatments,
respectively. Therapy consisted of two treatments that were
administered immediately following imaging at baseline and on
day 3. Each treatment included an intra-peritoneal injection (total
volume of 100 μL) of trastuzumab (10 mg/kg) or saline vehicle.
(A dose of 10 mg/kg was chosen to approximate the clinical dose
currently given to breast cancer patients [8,28,29].) Prior to this
study, a dose-response analysis was utilized to evaluate and confirm
BT474 tumors in response to trastuzumab (10 mg/kg) treatment.
With trastuzumab treatment two times per week, treated mice
(N = 4) experienced at least 50% regression in tumor size by day 8,
while untreated (N = 4) experienced 40% increase in tumor
volume [30].
Data Acquisition
All MRI data were collected using a 7 T MRI scanner (Agilent
Technologies (formally Varian), Palo Alto, CA) equipped with a
38-mm quadrature RF coil (Doty Scientific, Columbia, SC).
Animal respiration rate was monitored, and body temperature
was maintained at 37°C by means of a flow of warm air directly
into the bore of the magnet. Each animal was placed in a custom
built restraint, and the tumor region was first localized via 3D
gradient echo scout images. T2-weighted images covering the
entire tumor volume were acquired using a fast spin-echo pulse
sequence with the following parameters: TR = 5500 ms, effective
TE = 35.6 ms, 1 mm slice thickness, and an acquisition matrix of
128 × 128 over a 28 × 28 mm2 field of view yielding a voxel size
of 0.22 × 0.22 × 1 mm3.
Diffusion-weighted images were acquired using a standard
pulsed gradient spin echo sequence with three b values (150, 500,
and 800 s/mm2) and gradients applied simultaneously along three
orthogonal directions (x, y, and z). Scan acquisition parameters were:
TR/TE = 2000/30 ms, gradient duration δ = 3 ms, gradient interval Δ =
20ms, two signal excitations, 15 onemm thick slices, and an acquisition
matrix of 64 × 64 over a 28 × 28 mm2 field of view yielding a voxel size
of 0.44 × 0.44 × 1 mm3. Image acquisition was triggered with
respiration and navigator corrected [31] to reduce image artifacts due to
bulk motion.
After DW-MRI, precontrast T1 maps were obtained via an
inversion recovery fast low angle shot gradient echo sequence
with an adiabatic inversion pulse and seven inversion times: 0.25,
0.45, 0.83, 1.5, 2.7, 5.0, and 10 seconds. The imaging
parameters were as follows: TR/TE/α = 12,000 ms/2.1 ms/15°,
NEX = 2, 15 one mm thick slices, an acquisition matrix of 64 ×
64, and a 28 × 28 mm2 FOV yielding a voxel size of 0.44 × 0.44
× 1 mm3. Dynamic T1-weighted images were acquired using a
spoiled gradient echo sequence at a temporal resolution of 12.8
seconds for 20 minutes with the following parameters: TR/TE/α =
100 ms/2.1 ms/25°, NEX = 2, and the same acquisition matrix and
FOV as the precontrast T1 map. A bolus of 0.05 mmol/kg Gd-
DTPA was delivered via a jugular catheter using an automated
syringe pump (Harvard Apparatus, Holliston, MA) at a rate of
2.4 mL/min after 2 minutes of baseline images were acquired.Data Analysis
ADC parametric maps were constructed by fitting the MR signal
intensities from images acquired at three b values using a nonlinear
least squares optimization method to Eq. (1):
S bð Þ ¼ S0  e ‐ADC b; ð1Þ
where S0 and S(b) are the signal intensities before and after
application of the diffusion gradients, respectively. The median
ADC was quantified from the whole tumor volume. If the ADC of
the water phantom was greater than ±15% of free water at 37°C [32],
then the corresponding tumor ADC slice was removed from the DW-
MRI analysis. All DW-MRI data analysis methods were performed in
MATLAB® (version R2013b; The MathWorks, Natick, MA). Voxels
were removed from the DW-MRI analysis if the fitting route yielded
an ADC value less than zero or greater than 3×10−3 mm2/sec.
Data collected for the T1 map were fit for every image voxel using a
nonlinear least squares method to the following equation:
S ¼ S0  1‐2  eTI=T1
 
; ð2Þ
where S0 and S are the signal intensities at thermal equilibrium and
inversion time, respectively, and TI is the inversion time. Once T1
maps were calculated, signal intensity time courses from all tumor
voxels were fit to the standard two-compartment Tofts-Kety model to
extract pharmacokinetic parameters [33,34] which is given by Eq. (3):
Ct tð Þ¼Ktrans
Zt
0
Cp uð Þ  e− K
trans=veð Þ tuð Þdu; ð3Þ
where Ct and Cp are the concentrations of the contrast agent in the
tissue and plasma compartment, respectively, Ktrans is the volume
transfer constant between Cp and Ct, and ve is the extravascular
extracellular volume fraction.
The signal intensity time courses from each voxel were fit to Eq. (3)
using a nonlinear least squares approach by incorporating: 1) the
precontrast T1 value, 2) the fast exchange limit model [22] with
relaxivity for gadopentetate at 7 T, r1 = 4.72 mM
−1 s−1 [35], and 3) a
population-derived vascular input function collected from a cohort of
10 athymic female mice using the identical protocol described by
Loveless et al. [35]. Additionally, the population-derived vascular
input function was individualized for each animal in the current study
using the method previously described [36]. Briefly, a ROI was drawn
across three slices in the muscle to generate an averaged signal
intensity time course. This time course was then fit to the two-
compartment model in an iterative fashion until the ve of the muscle
equaled a physiologically relevant value (i.e., 0.11) [37]. Voxels were
removed from the DCE-MRI analysis if the fitting routine yielded a
Ktrans value less than 0.01 min−1 or greater than 5 min−1, and a
ve value greater than 1.
Histological Analysis
All animals were sacrificed after the final imaging time point on day
4 and tumors were excised. Tumors were placed in tissue cassettes and
fixed in 10% formalin, before being stored in 70% ethanol. Serial
sections of tumor (5 μm thick) were cut from the central slices of
paraffin-embedded tissue blocks and floated onto charged glass slides
and dried overnight. A hematoxylin and eosin (H&E) stained section
was obtained from the tissue block. Following antigen retrieval on the
Translational Oncology Vol. 7, No. 6, 2014 DW-MRI and DCE-MRI in HER2-overexpressing human breast cancer xenografts Whisenant et al. 771remaining sections, the tissue sections were stained with anti-CD31
(ab28364, Abcam Cambridge, MA) or anti-Ki67 (M7240, Dako
Carpinteria, CA). Slides were digitally scanned in high resolution
(20×) brightfield with a Leica (Leica Microsystems Inc, Ariol, Buffalo
Grove, IL) SCN400 Slide Scanner. H&E sections were examined for
cellular necrosis and reported as a percentage of tumor cross-sectional
area. Necrotic tissue within the tumor was manually segmented, and
percent necrosis was reported as the ratio of the segmented area to
total tumor area (Image J, Softonic, San Francisco, CA). The
associated software with the Leica SCN400 package was utilized for
unbiased, automated image analysis and quantification of immuno-
staining in brightfield. Using H&E sections, four regions of viable
tissue were selected (total area = 1.53 mm2); the four regions were
applied to the corresponding Ki67 and CD31 slides using a linking
tool to ensure comparable regions of tissue were analyzed for all
histology quantification. The program was trained to select
microvessel, proliferation, and nuclei based on coloring and size.
Microvessel density was examined through analysis of total micro-
vessels per area through CD31 staining. Cellular density was
calculated as the total number of nuclei per square millimeter
detected within the four viable regions of tissue on the H&E stained
sections. Cell proliferation (Ki67 staining) was calculated as the
percentage of proliferating nuclei per total nuclei detected within the
four viable tissue regions on the Ki67 stained sections of tumor.Figure 1. Tumor volume changes are shown for the following
comparisons: (A) BT474 Treated vs. BT474 Control, (B) BT474
Treated vs. HR6 Treated, and (C) HR6 Treated vs. HR6 Control.
There are no significant differences in tumor volumes between anyStatistical Analysis
To assess group changes in tumor volume, ROIs were manually
drawn along tumor boundaries obtained from the high resolution
anatomical MR images from all slices consisting of tumor tissue. The
same ROIs were copied to the DW-MRI and DCE-MRI data,
and the median ADC, Ktrans, and ve were quantified from the
tumor ROIs.
The analysis of variance repeated measures with Sidak test to correct for
multiple comparisons was used to compare: 1) trastuzumab versus vehicle
BT474, 2) treated BT474 versus treated HR6, and 3) trastuzumab versus
vehicle treatedHR6 cohorts. Statistical analysis was only performed on the
percent change data using GraphPad Prism version 6.00 for Windows
(GraphPad Software Inc., La Jolla, CA). Differences in the immunohis-
tological data and tumor volume were also tested for significance using
analysis of variance repeated measures with Sidak test to correct for
multiple comparisons; P b .05 was taken as the significance threshold. All
data are presented as mean ± standard error of the mean (SEM).of the cohort comparisons on day 1 (P N .05). Percent change in
tumor volume is significantly lower in the treated BT474 cohort
compared to both the BT474 controls (P b .0001) and the HR6
treated (P b .0001) animals on day 4. Additionally, tumor volume is
significantly higher in the HR6 control compared to HR6 treated
tumors (P b .0001) on day 4. *P b .05.Results
The percent change in tumor volumes at each imaging time point are
displayed for each cohort in Figure 1; absolute values and percent
change from baseline are presented for each group and time point in
Table 1. The number of mice for each cohort and time point is
displayed for each imaging parameter in Tables 2 to 4. Longitudinal
percent changes in tumor volume for the treated and control BT474
tumors are displayed on Figure 1A; significant differences in changes
in tumor volume between these groups were not observed at baseline
or day 1 (P N .05), but were significantly different at day 4
(P b .0001). Percent change in tumor volume at each time point is
displayed in Figure 1B for the treated BT474 and treated HR6
tumors. Significant differences between changes in tumor volume in
these cohorts were not observed at baseline or day 1 (P N .05), butwere significant at day 4 (P b .0001). Lastly, longitudinal percent
changes in tumor volume for the treated and control HR6 tumors are
displayed in Figure 1C; a significant difference in changes in tumor
volume was not observed at baseline or day 1 (P N .05), but a
significant difference was observed on day 4 (P b .0001).
DW-MRI Analysis
ADC maps were constructed and are displayed in Figure 2 as
overlays on T2-weighted anatomical images; absolute ADC values
Table 3. Average Ktrans Values (and Percent Change +/- SEM from Baseline) for Each Group on
Baseline, day 1, and day 4
Treatment Group Baseline (min−1) Day 1 (min−1) Day 4 (min−1)
BT474 treated 0.19 ± 0.02 (N = 12) 0.22 ± 0.03 (N = 12)
(14.57 ± 12.91%)
0.31 ± 0.03 (N = 7)
(53.53 ± 11.63%)
HR6 treated 0.14 ± 0.02 (N = 5) 0.10 ± 0.01 (N = 5)
(−25.39 ± 9.17%)
0.19 ± 0.04 (N = 5)
(38.93 ± 26.77%)
BT474 control 0.18 ± 0.04 (N = 8) 0.17 ± 0.02 (N = 7)
(12.35 ± 24.17%)
0.14 ± 0.02 (N = 6)
(−12.68 ± 21.15%)
HR6 control 0.13 ± 0.02 (N = 6) 0.11 ± 0.01 (N = 6)
(3.58 ± 16.67%)
0.14 ± 0.02 (N = 5)
(33.32 ± 21.02%)
Table 1. Tumor Volume (and Percent Change +/− SEM from Baseline) for Each Group on
Baseline, day 1, and day 4
Animal Cohort Baseline (×10−4 mm2/s) Day 1 (×10−4 mm2/s) Day 4 (×10−4 mm2/s)
BT474 treated 232 ± 29 219 ± 27
(−6.31 ± 2.11%)
145 ± 28
(−38.3 ± 7.14%)
HR6 treated 296 ± 45 302 ± 46
(2.42 ± 1.56%)
289 ± 48
(−3.47 ± 2.48%)
BT474 control 200 ± 38 227 ± 35
(2.02 ± 1.62%)
229 ± 45
(−0.57 ± 5.13%)
HR6 control 376 ± 39 411 ± 43
(9.10 ± 1.62%)
445 ± 52
(17.0 ± 3.70%)
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each group and imaging time point in Table 2. One representative
animal from each cohort is displayed in each of four rows (BT474
treated, HR6 treated, BT474 control, and HR6 control, respectively),
whereas each column represents an imaging time point (baseline, day
1, and day 4, respectively). Qualitatively, the ADC parametric maps
show little change in the BT474 treated and control groups, and an
increase over time in both HR6 cohorts.
Comparison of the ADC data between the BT474 treated and
control groups, as seen in Figure 3A, demonstrated no significant
differences at any time point during the study (P N .05). There were
no significant differences between the BT474 treated and HR6
treated cohorts on day 1 (P = .61). On Day 4, however, ADC was
significantly higher (P = .003) in the HR6 treated group, as seen in
Figure 3B. Comparison of the treated and control nonresponder HR6
groups, as seen in Figure 3C, revealed no significant differences
between the groups on any of the days (P N .05).
DCE-MRI Analysis
Parametric maps of Ktrans and ve were constructed and overlaid on
T2-weighted anatomical images, and are displayed in Figure 4A and
B, respectively. Similarly to the DW-MRI data, one representative
animal from each cohort is displayed in each of four rows of Figure 4,
while the columns represent the different imaging time points.
Qualitatively, these maps illustrate a longitudinal increase in Ktrans for
the treated BT474 cohort and a decrease in the BT474 controls.
Ktrans appears to increase over the imaging time points in the treated
HR6 animal, while remaining relatively unchanged in the control
HR6 animal.
The parametric maps of ve reveal longitudinal increases in the
BT474 treated groups, while their control cohorts show relatively
no changes. However, the parametric maps of the treated and
control HR6 cohorts reveal a longitudinal increase in ve, as well as
large regions that contain voxels with physiologically implausibleTable 2. Average ADC Values (and Percent Change +/− SEM from Baseline) for Each Treatment
Group on Baseline, day 1, and day 4
Animal Cohort Baseline (×10−4 mm2/s) Day 1 (×10−4 mm2/s) Day 4 (×10−4 mm2/s)
BT474 treated 6.90 ± 0.30 (N = 11) 7.59 ± 0.40 (N = 10)
(8.86 ± 10.30%)
8.06 ± 0.35 (N = 8)
(15.52 ± 22.59%)
HR6 treated 6.18 ± 0.36 (N = 5) 7.42 ± 0.39 (N = 5)
(21.48 ± 5.04%)
9.80 ± 0.71 (N = 4)
(56.85 ± 15.91%)
BT474 control 6.44 ± 0.26 (N = 8) 7.10 ± 0.49 (N = 6)
(14.91 ± 14.33%)
6.75 ± 0.58 (N = 5)
(11.94 ± 14.66%)
HR6 control 7.29 ± 0.66 (N = 7) 6.96 ± 0.40 (N = 7)
(0.29 ± 9.91%)
8.09 ± 0.30 (N = 5)
(27.89 ± 22.28%)values (i.e., ve N 1), which is probably due to an increase in
necrosis. These voxels are set to zero and removed from the
quantitative DCE-MRI analysis.
The absolute values and percent change from baseline (mean ±
SEM) are presented for each group and imaging time point in Tables 3
and 4 for Ktrans and ve, respectively. The percent change in K
trans was
not significantly different between treated and control BT474 cohorts
on day 1 (Figure 5A; P = .99). However, on day 4, Ktrans was
significantly elevated in the treated BT474 tumors compared to their
control counterparts (Figure 5A; P = .02). Ktrans was not significantly
different at day 1 or day 4 between the treated BT474 and HR6
cohorts (Figure 5B; P N .05). Additionally, no significant differences in
Ktrans were observed between treated and control HR6 tumors at any
time point during the study (Figure 5C; P N .05).
The ve of the treated BT474 cohort was significantly higher on day
1 (Figure 5D; P = .002) and day 4 (Figure 5D; P = .0007) compared
to BT474 controls, revealing an early response detected by imaging
prior to changes in tumor size. Additionally, ve was significantly
higher on day 1 in the treated BT474 compared to the treated HR6
cohort (Figure 5E; P = 0.004) though it was not significantly different
at day 4 (Figure 5E; P = .61). The ve values in the HR6 treated group
were not significantly different compared to their control counter-
parts at any time point (Figure 5F; P N .05).
Histological Analysis
Histological analysis was performed on tissue obtained at day 4 after
the final imaging time point. Representative images of H&E, Ki67, and
CD31 are shown in Figure 6. A qualitative assessment of histology
stains shows that the BT474 treated group has less cells undergoing
proliferation (Ki67 stain; Figure 6, panelB) compared to the other three
groups (Figure 6, E, H, and K). Also, the treated BT474 and HR6
groups appear to have more microvessels (CD31 stain; Figure 6,C and I)
in comparison to their untreated counterparts (Figure 6, F and L). It is
also interesting that theHR6 tumors (both treated and control) appear toTable 4. Average ve Values (and Percent Change +/- SEM from Baseline) for Each Group on
Baseline, day 1, and day 4
Treatment Group Baseline Day 1 Day 4
BT474 treated 0.27 ± 0.03 (N = 12) 0.38 ± 0.04 (N = 12)
(54.73 ± 12.91%)
0.47 ± 0.04 (N = 7)
(71.77 ± 14.84%)
HR6 treated 0.35 ± 0.01 (N = 5) 0.31 ± 0.04 (N = 5)
(−12.02 ± 9.11%)
0.51 ± 0.04 (N = 5)
(47.78 ± 13.40%)
BT474 control 0.29 ± 0.03 (N = 8) 0.29 ± 0.03 (N = 7)
(−2.10 ± 10.57%)
0.29 ± 0.03 (N = 6)
(−2.67 ± 11.70%)
HR6 control 0.28 ± 0.06 (N = 6) 0.31 ± 0.03 (N = 6)
(21.86 ± 13.60%)
0.36 ± 0.03 (N = 5)
(53.07 ± 38.43%)
Figure 2. DW-MRI ADC parametric maps of a representative mouse from each cohort. The columns indicate baseline, day 1, and day 4
time points whereas each row indicates each of the four groups. Regions with noticeably increased ADC values are observed within the
center of the treated and control HR6 cohorts, indicating possible areas of cell death (necrosis).
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compared to both BT474 cohorts.
Visual assessment of overall cell density, percent proliferation, and
microvessel density (Figure 6) are consistent with the quantitative
assessment shown in Figure 7. Comparing the BT474 treated
and control cohorts, there were no significant differences in cell
density (P N .99, Figure 7A) or necrosis (P = .98, Figure 7B).
Furthermore, HR6 treated and control groups also exhibited no
significant differences in cell density (P = .99, Figure 7A) or necrosis
(P N .99, Figure 7B). Interestingly, there is less (−48.3%) cell density
in the HR6 control group as compared to the BT474 control group
(P = .10). There is also a higher, yet not significant, percent necrosis
(P = 0.71) in the HR6 control tumors compared to the BT474
control groups. Ki67 analysis showed significantly less proliferation in
the BT474 treated tumors compared to BT474 control (Figure 7C,
P = .05). Additionally, the difference in Ki67 staining between
BT474 treated and HR6 treated was significantly different (P = .005,
Figure 7C), with the HR6 treated group demonstrating 52.4%
proliferation compared to 18.7% in the BT474 treated. There were
no significant proliferation differences between HR6 treated and
control tumors (P = .40, Figure 7C). BT474 treated and HR6 treated
tumors reveal a slightly greater, yet not significant, microvessel
density (microvessels per area) compared to their control counterparts
(P = .84 and P = .32, respectively), as seen in Figure 7D.Discussion
The main mechanism of action of trastuzumab appears to be the
disruption of downstream cell signaling pathways leading to
inhibition of cellular proliferation and survival [2,4]. A secondary
mechanism of action has been observed where trastuzumab acts as an
anti-angiogenic agent to reduce vascular volume and flow [11]. The
former observation will necessarily occur earlier than changes in
tumor size. Additionally, treatment-induced changes in tumor
vasculature might also occur prior to changes in tumor morphology.
A unique advantage of imaging tumor physiology is that quantitative
functional and molecular imaging techniques have the ability to
capture treatment-induced changes before any volumetric changes in
tumor growth are observed, thereby providing an early response
assessment. Thus, the goal of this study was to examine the sensitivity
of DW-MRI and DCE-MRI to the anti-tumor and anti-angiogenic
effect of trastuzumab on xenograft models that are sensitive (BT474)
and resistant (HR6) to trastuzumab.
As they are defined, the ADC and DCE-MRI pharmacokinetic
parameter ve reflect changes in tumor cytoarchitecture and cell density;
therefore, we hypothesized that the ADC and ve would reflect the anti-
proliferative effect of trastuzumab. A quantitative analysis of the DCE-
MRI data revealed a significantly higher ve on day 1 in the BT474
treated group compared to its control counterpart (Figure 5D; BT474
control) and its resistant counterpart (Figure 5E; HR6). This
Figure 3. Percent change in ADC measurements are shown for the
following comparisons: (A) BT474 Treated vs. BT474 Control,
(B) BT474 Treated vs. HR6 Treated, and (C) HR6 Treated vs. HR6
Control. No significant differences in ADC are observed at any time
point between the BT474 cohorts (P N .05). ADC is significantly
higher in the HR6 treated tumors as compared to the BT474 treated
tumors on day 4 (P = .004). Although no significant differences in
ADC were observed between the HR6 cohorts, ADC increased
longitudinally in both cohorts. *P b .05.
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tumor size that occurred on day 4 (Figure 1A and B). Significant
differences in ADC were not observed between the treated and control
BT474 cohorts (Figure 3A). This result is not unique, as Aliu et al. did
not observe significant changes in the ADC values of BT474 mice at 4
days post gefitinib treatment [18]. However, there are studies that have
used ADC to accurately separate treated from control cohorts in
preclinical models of basil-like breast cancer [17]; however, these
significant changes in ADC were observed at later time points (day 7)
after therapy.
Interestingly, the trastuzumab-resistant cohort that received
therapy (i.e., treated HR6) exhibited a significantly higher ADC atday 4 (P = 0.004) compared to the BT474 treated group (Figure 3B).
Furthermore, the ADC values in both the HR6 cohorts showed
similar increasing longitudinal trends, although they were not
significantly different from each other. We hypothesize the increase
in ADC is due to a less cell density and greater percent necrosis, which
was confirmed from the histological data (Figure 7A and B).
Additionally, observational differences in the ADC and ve were
noticed when comparing the non-treated cohorts; i.e., BT474 control
versus HR6 control (this comparison was not statistically compared)
(Tables 1 and 3). Less cell density and more necrosis would allow for
an increase in water diffusion (ADC) and extravascular extracellular
volume fraction (ve), which are reflective of the differences within
each tumor type. Moreover, the quantitative analysis of ADC
included the entire tumor (did not exclude a necrotic core), as there
are currently no validated or consistently utilized methods to reliably
isolate necrotic tissue in subcutaneous tumors, although different
approaches have been explored [18,38]. Additionally, it is not
currently possible to differentiate between necrosis that developed
from the xenograft tumors outgrowing their blood supply and
necrosis resulting in response to trastuzumab treatment.
Ki67 staining followed the hypothesized trends as only the
trastuzumab-sensitive treated group (i.e., treated BT474) revealed a
significantly lower amount of Ki67 staining, which equated to less
than 20% of the cells undergoing proliferation (Figure 7C). The
BT474 control, HR6 treated, and HR6 control groups demonstrated
over 40% of the total cells undergoing proliferation. The Ki67
histological results confirm treatment response revealing that
trastuzumab is significantly affecting the cellular proliferation in the
BT474 trastuzumab-sensitive model, and that the trastuzumab-
resistant groups appear to be resistant.
To investigate the sensitivity of DCE-MRI to the anti-angiogenic
effect of trastuzumab, we evaluated the longitudinal trends of the
pharmacokinetic parameter Ktrans, which provides a measurement of
tumor microvascular flow and permeability. We hypothesized that
Ktrans would decrease in response to effective treatment. However, the
opposite was observed as Ktrans was significantly larger in the
trastuzumab-responsive treated group (i.e., BT474 treated) compared
to controls (Figure 5A). The microvessel density quantified from
CD31 staining was larger, yet not significant, in the BT474 treated
group (Figure 7D), which corresponded with the imaging data. These
two results were interesting and unexpected considering previous
studies observed a potential decrease in vascularity [11,12]. We
hypothesize that these changes in Ktrans and CD31 microvessel
density links trastuzumab therapy to altering vascular function (i.e.,
perfusion and permeability), and could possibly be utilized to
improve the delivery of (for example) cytotoxic therapy in the future
[39,40]; this is the subject of an ongoing investigation in our lab [40].
Trastuzumab has been previously identified as having anti-angiogenic
affects in general, and vascular normalization in particular [11]. Vascular
normalization is the process of utilizing anti-angiogenic agents to
transiently stabilize the abnormal tumor vasculature through balancing
the pro- and anti-angiogenic factors. In turn, this creates a more normal
vascular phenotype to temporarily improve intratumoral drug delivery.
Izumi et al. showed that trastuzumab causes blood vessels within the
HER2+ tumor (MDA-MB-361 breast cancer cells derived from brain
metastasis implanted grown in cranial windows) to more closely resemble
a normal phenotype [11]; a significant reduction in both the diameter of
the vessels and the vascular permeability was shown by day 15 (tumors
were treated with trastuzumab every three days with 30 mg/kg). Vessel
Figure 4. DCE-MRI parametric maps, (A) Ktrans and (B) ve, of a representative mouse from each group. The columns indicate baseline, day
1, and day 4 time points whereas each row indicates each of the four groups. Ktrans parametric maps reveal enhancement along the
periphery with increasing trends in the BT474 treated group. Ktrans parametric maps remain fairly consistent in HR6 treated groups, while
the BT474 control and HR6 control groups slightly decrease over time. ve parametric maps reveal variations within all the observed
tumors, with increased levels in the treated groups compared to controls.
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Figure 5. DCE-MRI parameters, Ktrans and ve, reveal significant differences between the animal groups. Shown are comparisons between
(A, D) BT474 Treated vs. BT474 Control, (B, E) BT474 Treated vs. HR6 Treated, and (C, F) HR6 Treated vs. HR6 Control. ve is significantly
higher in the BT474 treated group compared to both the BT474 control and the HR6 treated groups on day 1 (P = .002, P = .004,
respectively). Both Ktrans and ve reveal increasing trends in the BT474 treated group compared to its control counterpart on day 4 (P= .02,
P = .007, respectively). No significant differences in either of the DCE-MRI parameters were observed between the HR6 treated and
control groups. *P b .05.
776 DW-MRI and DCE-MRI in HER2-overexpressing human breast cancer xenografts Whisenant et al. Translational Oncology Vol. 7, No. 6, 2014diameter and volume was 2.8-fold and 6.6-fold less in the trastuzumab
treated tumors compared to control tumors, while trastuzumab also
increased survival by 65%compared to controls. To investigate these anti-
angiogenic effects, angiogenesis-related genes were investigated; trastzu-
mab-treated tumors revealed lower levels of VEGF, TGF-α, Ang-1, PAI-
1, and higher levels of TSP-1 compared to control tumors [11,41]. A
study byHeyerdahl et al. analyzed changes inDCE-MRI parameters after
227Th-trastuzumab radiotherapy in xenograft tumors [42]. Although
radiotherapy has the potential to increase permeability and damage
vasculature, the tumors treated with trastuzumab labeled 227Th were well
perfused and exhibited vascular stability [42]. This study also revealed a
significant increase in kep (=K
trans/ve; the rate of contrast wash-out from
extracellular space to plasma) compared to control tumors on week two
and three. This more normal phenotype in a tumor could potentially be
indicating vascular normalization. These previous studies in combination
with our data indicate that further, prospective, studies on trastuzumab-
induced normalization is of interest; a study on this topic is currently
underway in our laboratory [40].Voxels which returned physiologically implausible values form the
DCE-MRI analysis (i.e., ve N 1) were removed from the statistical
analysis. A possible source of this issue is that the contrast agent is
being delivered via a diffusion mechanism rather than perfusion,
which is the case in completely necrotic tissues or cystic fluid. Thus,
this study is limited by the accuracy of the Tofts-Kety model in
regions of tissue where there is no active perfusion since this model
does not account for diffusion. Although there are initial efforts at
developing new models that account for contrast agent diffusion
[43,44], the Tofts-Kety equation is still the most common method for
the quantitative analysis of DCE-MRI data.
Another limitation of the longitudinal study design prevented
biological validation at each imaging time point (histology was only
taken at day 4); however, this was necessary to quantify longitudinal
changes in imaging biomarkers. Follow-up studies will directly match
histological samples with each particular imaging time point
throughout the study. Accurately characterizing the hypothesized
window's opening and closing would allow for optimization of
Figure 6. Sample staining (at 20× magnification) for H&E (first column), Ki67 (second column), and CD31 (third column) are shown for
BT474 treated (row one), BT474 control (row two), HR6 treated (row three), and HR6 control (row four). Representative images reveal that
BT474 tumors (treated and control) exhibit increased cell density compared to the HR6 tumors (treated: panels A and G and control:
panels D & J). Additionally, these images reveal decreased proliferation (panel B) in the BT474 treated cohort compared to the BT474
controls (panel E).
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therefore enhancing drug efficiency without increasing dosage. Thus,
important data related to the dynamic and transient nature of the
imaging parameters may have been missed in the current study.
Again, experiments are ongoing to address this issue.
Conclusions
The goal of this study was to evaluate the ability of DW-MRI and
DCE-MRI to measure the anti-proliferative and anti-vascular effects
of trastuzumab before changes in tumor size became evident in
responsive and resistant HER2+ breast cancer xenograft models. As
hypothesized, ve values were significantly greater at day 1 and day 4 in
response to treatment in the trastuzumab-responsive xenografts
compared to controls (P b .05). The significant difference observed
on day 1 preceded significant changes in tumor volume that occurred
at day 4; therefore, ve was an early marker of response in trastuzumab-
responsive xenografts. These imaging results on day 4 were supported
by histology. Additionally, ve was significantly higher in the BT474
treated group compared to the HR6 treated group at day 1, whichagain preceded tumor volume changes. Thus, ve is an early imaging
biomarker of response to treatment between xenografts with different
trastuzumab sensitivities. Although the heightened values in ADC
and ve within the treated and control trastuzumab-resistant groups
were unexpected, histological analysis showed a (non-significant)
lower cell density and higher percent necrosis when compared to the
trastuzumab-responsive counterparts. The DCE-MRI pharmacoki-
netic parameter Ktrans differentiated the treated and control BT474
xenografts; however, the significantly (P = .02) higher Ktrans observed
in response to trastuzumab was unexpected and hypothesized to be
related to vascular normalization. If proven true, this has opportunity
for real clinical impact as the development of imaging methods that
can non-invasively identify an optimum window of when to
administer, for example, chemotherapy would greatly benefit
patient care.
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